Updated annually, the British Pharmacopoeia (BP) is the only comprehensive collection of authoritative official standards for UK pharmaceutical substances and medicinal products.
It includes approximately 4,000 monographs which are legally enforced by the Human Medicines Regulations 2012. Medicinal products or active pharmaceutical ingredients sold or supplied in the UK must comply with the relevant monograph.
All monographs and requirements of the European Pharmacopoeia (Ph. Eur.) are reproduced in the BP, making the BP a convenient and fully comprehensive set of standards that can be used across Europe and beyond.
New for the BP 2023
The BP 2023 supersedes the BP 2022 and becomes legally effective on 1 January 2023. This edition incorporates new monographs from both the BP and Ph. Eur. along with a significant number of revised monographs.
Monographs and content:
- 23 new BP monographs, 59 new Ph. Eur. monographs.
- 151 amended BP monographs.
- All monographs from the Ph. Eur. 10th edition as amended by Supplements 10.1 to 10.8 are included.
- Ph. Eur. supplements 11.0, 11.1, and 11.2 included as in-year online and download product updates.
Key customer groups
The BP is a must have for suppliers and sellers of active pharmaceutical ingredients and medicinal products into the UK. For corporate pharmaceutical organisations to develop high-quality medicinal products in compliance with regulations, the BP 2023 features a variety of important monograph updates providing users with the information they need to maintain compliance.
Key corporate customers include: Pharmaceutical researchers and manufacturers, pharmacists, biotechnologists, quality assurance and quality controls inspectors, laboratory technicians and regulatory bodies.
Specialist researchers and lecturers in the field of pharmacy, analytical chemistry, biological science, biochemistry and pharmaceutical science can use the BP for research into medicinal products using the most up-to-date monographs.